Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijom.2007.01.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evolution of Mechanical Circulatory Support for advanced heart failure.
Prog Cardiovasc Dis
March 2024
Division of Cardiology, Department of Medicine, Advanced Cardiac Care, Columbia University Irving Medical Center, NY, USA. Electronic address:
Article Synopsis
- The review discusses the evolution of Left Ventricular Assist Devices (LVADs) from older pulsatile systems to newer continuous-flow devices like the HeartMate 3 (HM3), which have improved survival rates and quality of life for heart failure patients.
- It highlights the dual use of LVADs as both a bridge to transplant and as destination therapy, noting the reduction in complications, particularly hemocompatibility-related adverse events with the HM3.
- The review also addresses challenges such as infections and complications, introduces risk assessment tools for better patient care, and discusses future technologies that could revolutionize LVAD therapy and heart failure management.
The clinical impact of tricuspid regurgitation in patients with a biatrial orthotopic heart transplant.
Front Med
June 2023
Department of Cardiology, Erasmus MC, 3000 CA, Rotterdam, The Netherlands.
In this study, we aim to elucidate the clinical impact and long-term course of tricuspid regurgitation (TR), taking into account its dynamic nature, after biatrial orthotopic heart transplant (OHT). All consecutive adult patients undergoing biatrial OHT (1984-2017) with an available follow-up echocardiogram were included. Mixed-models were used to model the evolution of TR.
View Article and Find Full Text PDFLights and shadows of subcutaneous implantable cardioverter-defibrillator in Brugada syndrome.
Heart Rhythm
February 2023
Heart Rhythm Management Centre, UZ Brussel - VUB, Brussels, Belgium.
Currently the cornerstone of therapy for ventricular arrhythmic complications and sudden cardiac death prevention in Brugada syndrome (BrS) is an implantable cardioverter-defibrillator (ICD). BrS patient population differs from the majority of patients with an ICD implanted for structural heart disease, and as widely known, transvenous ICD (TV-ICD) systems have been associated with high complication rates in patients with BrS. Technological evolution of these devices has certainly reduced complications due to the device itself, but a careful preimplant screening of these patients is still essential.
View Article and Find Full Text PDFThird Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report: Preimplant Characteristics and Outcomes.
Ann Thorac Surg
April 2019
Department of Cardiology, Children's Hospital Boston, Boston, Massachusetts.
Background: The influence of ventricular assist device (VAD) use in the care of children with end-stage heart failure is growing rapidly through increasing numbers, new devices, expanding indications, and improving outcomes. Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs), a National Institutes of Health-sponsored United States database, provides a platform to understand this emerging population.
Methods: Between September 19, 2012, and December 31, 2017, 30 hospitals implanted 508 devices in 423 patients aged younger than 19 years.
Relationship between early inflammatory response and clinical evolution of the severe multiorgan failure in mechanical circulatory support-treated patients.
Mediators Inflamm
April 2015
CardioThoracic and Vascular Department, Niguarda Cà Granda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.
Background: The mechanical circulatory support (MCS) is an effective treatment in critically ill patients with end-stage heart failure (ESHF) that, however, may cause a severe multiorgan failure syndrome (MOFS) in these subjects. The impact of altered inflammatory response, associated to MOFS, on clinical evolution of MCS postimplantation patients has not been yet clarified.
Methods: Circulating cytokines, adhesion molecules, and a marker of monocyte activation (neopterin) were determined in 53 MCS-treated patients, at preimplant and until 2 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!